Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 12.53B 707M 621M 585M 534M 992M 67.69B 1.01B 7.01B 2.71B 34.59B 2.65B 2.6B 111B P/E 2026 *
6.79x
P/E 2027 * 6.51x
Enterprise Value 16.72B 943M 828M 781M 712M 1.32B 90.33B 1.35B 9.35B 3.62B 46.16B 3.54B 3.46B 148B EV / Sales 2026 *
0.93x
EV / Sales 2027 * 0.86x
Free-Float
68.95%
Yield 2026 *
6.23%
Yield 2027 * 8.34%
1 day-0.08%
1 week+3.71%
Current month-2.65%
1 month-4.89%
3 months-14.10%
6 months-27.03%
Current year-28.17%
1 week 12.22
Extreme 12.22
12.94
1 month 12.22
Extreme 12.22
13.67
Current year 12.22
Extreme 12.22
19.48
1 year 12.22
Extreme 12.22
19.49
3 years 12.22
Extreme 12.22
29.18
5 years 12.22
Extreme 12.22
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 11/04/2023
Director of Finance/CFO - 30/11/2015
Investor Relations Contact - 30/09/2019
Director TitleAgeSince
Chairman - 29/10/1996
Director/Board Member - 05/07/2010
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.08%+3.71%-31.83%-8.99% 707M
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.40%+1.07%+23.94%+42.72% 363.91B
Weighted average by Cap. +0.27%+1.32%+40.41%+68.20%

Financials

2026 *2027 *
Net sales 17.99B 1.01B 891M 840M 766M 1.42B 97.2B 1.45B 10.06B 3.9B 49.67B 3.81B 3.73B 160B 18.74B 1.06B 929M 875M 798M 1.48B 101B 1.51B 10.48B 4.06B 51.74B 3.97B 3.88B 166B
Net income 1.91B 107M 94.45M 89.02M 81.2M 151M 10.3B 153M 1.07B 413M 5.26B 404M 395M 16.9B 2.06B 116M 102M 96.13M 87.68M 163M 11.12B 166M 1.15B 446M 5.68B 436M 426M 18.25B
Net Debt 4.19B 236M 208M 196M 179M 332M 22.64B 337M 2.34B 908M 11.57B 887M 868M 37.16B 3.67B 207M 182M 171M 156M 290M 19.8B 295M 2.05B 794M 10.12B 776M 759M 32.51B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,658
Date Price Change Volume
25/09/26 MX$12.85 -0.08% 3,194,723
24/09/26 MX$12.86 +2.31% 4,157,460
23/09/26 MX$12.57 +0.32% 2,853,459
22/09/26 MX$12.53 +1.46% 2,718,666
21/09/26 MX$12.35 -0.32% 6,062,302
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.85MXN
Average target price
21.67MXN
Spread / Average Target
+68.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LAB B Stock